These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9602707)

  • 41. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
    Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
    BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p53 Mutation analysis of low-grade dysplasia and high-grade dysplasia/carcinoma in situ of the esophagus using laser capture microdissection.
    Kobayashi M; Kawachi H; Takizawa T; Uchida K; Sekine M; Kumagai J; Momma K; Nemoto T; Akashi T; Funata N; Eishi Y; Koike M
    Oncology; 2006; 71(3-4):237-45. PubMed ID: 17652955
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus.
    Lörinc E; Jakobsson B; Landberg G; Veress B
    Histopathology; 2005 Jun; 46(6):642-8. PubMed ID: 15910595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus.
    Akgun H; Lechago J; Younes M
    Anticancer Res; 2002; 22(3):1459-61. PubMed ID: 12168823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.
    Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S
    World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Barrett's oesophagus: endoscopic diagnosis and follow-up].
    Ponsot P
    Ann Chir; 2006 Jan; 131(1):3-6. PubMed ID: 16376849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.
    Fang M; Lew E; Klein M; Sebo T; Su Y; Goyal R
    Am J Gastroenterol; 2004 Oct; 99(10):1887-94. PubMed ID: 15447746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-grade dysplasia diagnosis ratio and progression metrics identify variable Barrett's esophagus risk stratification proficiency in independent pathology practices.
    Davison JM; Shah MB; Deitrick C; Chennat J; Fasanella KE; McGrath K
    Gastrointest Endosc; 2018 Nov; 88(5):807-815.e2. PubMed ID: 29944863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Oncogene amplification and genetic heterogeneity in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus].
    Walch A; Bink K; Hutzler P; Zitzelsberger H; Braselmann H; Aubele M; Höfler H; Werner M
    Verh Dtsch Ges Pathol; 2001; 85():257-63. PubMed ID: 11894407
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Esophageal polypoid dysplasia of gastric foveolar phenotype with focal intramucosal carcinoma associated with Barrett's esophagus.
    Asthana N; Mandich D; Ligato S
    Am J Surg Pathol; 2008 Oct; 32(10):1581-5. PubMed ID: 18724240
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.
    van Dekken H; Hop WC; Tilanus HW; Haringsma J; van der Valk H; Wink JC; Vissers KJ
    Am J Clin Pathol; 2008 Nov; 130(5):745-53. PubMed ID: 18854267
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett's Esophagus.
    Vennalaganti P; Kanakadandi V; Goldblum JR; Mathur SC; Patil DT; Offerhaus GJ; Meijer SL; Vieth M; Odze RD; Shreyas S; Parasa S; Gupta N; Repici A; Bansal A; Mohammad T; Sharma P
    Gastroenterology; 2017 Feb; 152(3):564-570.e4. PubMed ID: 27818167
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia.
    Overholt BF; Wang KK; Burdick JS; Lightdale CJ; Kimmey M; Nava HR; Sivak MV; Nishioka N; Barr H; Marcon N; Pedrosa M; Bronner MP; Grace M; Depot M;
    Gastrointest Endosc; 2007 Sep; 66(3):460-8. PubMed ID: 17643436
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.
    Conio M; Blanchi S; Lapertosa G; Ferraris R; Sablich R; Marchi S; D'Onofrio V; Lacchin T; Iaquinto G; Missale G; Ravelli P; Cestari R; Benedetti G; Macrì G; Fiocca R; Munizzi F; Filiberti R
    Am J Gastroenterol; 2003 Sep; 98(9):1931-9. PubMed ID: 14499768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study.
    Whittles CE; Biddlestone LR; Burton A; Barr H; Jankowski JA; Warner PJ; Shepherd NA
    J Pathol; 1999 Apr; 187(5):535-40. PubMed ID: 10398118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1.
    Karamchandani DM; Lehman HL; Ohanessian SE; Massé J; Welsh PA; Odze RD; Goldblum JR; Berg AS; Stairs DB
    Diagn Pathol; 2016 Feb; 11():23. PubMed ID: 26926447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
    Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Not all low grade dysplasia in Barrett's oesophagus is the same: using specific histological criteria in predicting progression to neoplasia.
    Tsoi EH; Williams RA; Christie M; Machet D; Deb S; Sundararajan V; Cameron GR; Desmond PV; Taylor ACF
    Pathology; 2021 Oct; 53(6):700-704. PubMed ID: 34420794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Computerized morphometry as an aid in determining the grade of dysplasia and progression to adenocarcinoma in Barrett's esophagus.
    Sabo E; Beck AH; Montgomery EA; Bhattacharya B; Meitner P; Wang JY; Resnick MB
    Lab Invest; 2006 Dec; 86(12):1261-71. PubMed ID: 17075582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.